

# Caffeine and physiological responses to submaximal exercise: a meta-analysis

| Journal:         | International Journal of Sports Physiology and Performance             |
|------------------|--|
| Manuscript ID    | IJSPP.2017-0312  |
| Manuscript Type: | Invited Brief Review   |
| Keywords:        | Ergogenic aids, methylxanthine, endurance exercise, adenosine receptor |
|                  |  |



| 1      | Caffeine and physiological responses to submaximal exercise: a meta-analysis                          |  |  |  |  |  |  |  |  |  |  |  |  |
|--------|---|--|--|--|--|--|--|--|--|--|--|--|--|
| 2      |   |  |  |  |  |  |  |  |  |  |  |  |  |
| 3      | Mark Glaister, Conor Gissane  |  |  |  |  |  |  |  |  |  |  |  |  |
| 4      |   |  |  |  |  |  |  |  |  |  |  |  |  |
| 5<br>6 | School of Sport, Health, and Applied Sciences, St Mary's University, Strawberry Hill, Twickenham, UK. |  |  |  |  |  |  |  |  |  |  |  |  |
| 7      |   |  |  |  |  |  |  |  |  |  |  |  |  |
| 8      | Corresponding Author:   |  |  |  |  |  |  |  |  |  |  |  |  |
| 9      | Dr Mark Glaister  |  |  |  |  |  |  |  |  |  |  |  |  |
| 10     | School of Sport, Health, and Applied Sciences   |  |  |  |  |  |  |  |  |  |  |  |  |
| 11     | St. Mary's University   |  |  |  |  |  |  |  |  |  |  |  |  |
| 12     | Waldegrave Road   |  |  |  |  |  |  |  |  |  |  |  |  |
| 13     | Strawberry Hill   |  |  |  |  |  |  |  |  |  |  |  |  |
| 14     | Twickenham  |  |  |  |  |  |  |  |  |  |  |  |  |
| 15     | UK  |  |  |  |  |  |  |  |  |  |  |  |  |
| 16     | TW1 4SX   |  |  |  |  |  |  |  |  |  |  |  |  |
| 17     | Tel: (+44)208 240 4012  |  |  |  |  |  |  |  |  |  |  |  |  |
| 18     | Fax: (+44)208 240 4212  |  |  |  |  |  |  |  |  |  |  |  |  |
| 19     | E-mail: mark.glaister@stmarys.ac.uk   |  |  |  |  |  |  |  |  |  |  |  |  |
| 20     |   |  |  |  |  |  |  |  |  |  |  |  |  |
| 21     | Running title: Physiological responses to caffeine  |  |  |  |  |  |  |  |  |  |  |  |  |
| 22     |   |  |  |  |  |  |  |  |  |  |  |  |  |
| 23     | Abstract only word count: 250   |  |  |  |  |  |  |  |  |  |  |  |  |
| 24     | Text only word count: 3191  |  |  |  |  |  |  |  |  |  |  |  |  |
| 25     | Number of figures: 3  |  |  |  |  |  |  |  |  |  |  |  |  |
| 26     | Number of tables: 2   |  |  |  |  |  |  |  |  |  |  |  |  |
| 27     |   |  |  |  |  |  |  |  |  |  |  |  |  |

#### 28 Abstract

29 The aim of this study was to carry out a systematic review and meta-analysis of the effects of 30 caffeine supplementation on physiological responses to submaximal exercise. 26 studies met the inclusion criteria of adopting double-blind, randomised, crossover designs that included a 31 sustained (5 - 30 minutes) fixed-intensity bout of submaximal exercise (constrained to 60 -32 85%  $\dot{VO}_{2max}$ ) using a standard caffeine dose of 3 – 6 mg kg<sup>-1</sup> administered 30 – 90 minutes 33 prior to exercise. Meta-analyses were completed using a random-effects model, and data are 34 presented as raw mean difference (D) with associated 95% confidence limits (CL<sub>95</sub>). Relative 35 to placebo, caffeine led to significant increases in submaximal measures of minute ventilation 36  $(D = +3.36 \text{ L} \cdot \text{min}^{-1}; \text{ CL}_{95}[+1.63, +5.08]; p = 0.0001; n = 73)$ , blood lactate (D = +0.69)37  $\text{mmol}\cdot\text{L}^{-1}$ ;  $\text{CL}_{95}[+0.46, +0.93]$ ; p < 0.00001; n = 208), and blood glucose ( $D = +0.42 \text{ mmol}\cdot\text{L}^{-1}$ ) 38 <sup>1</sup>; CL<sub>95</sub>[+0.29, +0.55]; p < 0.00001; n = 129). In contrast, caffeine had a suppressive effect on 39 ratings of perceived exertion (D = -0.8; CL<sub>95</sub>[-1.1, -0.6]; p < 0.00001; n = 147). Caffeine had 40 no effect on measures of heart rate (p = 0.99; n = 207), respiratory exchange ratio (p = 0.18; n 41 = 181), or VO<sub>2</sub> (p = 0.92; n = 203). The positive effects of caffeine supplementation on 42 sustained high-intensity exercise performance are widely accepted; though the mechanisms to 43 explain that response are currently unresolved. This meta-analysis has revealed clear effects 44 of caffeine on various physiological responses during submaximal exercise, which may help 45 to explain its ergogenic action. 46

47

- 48 *Key words*: Ergogenic aids, methylxanthine, endurance exercise, adenosine receptor.
- 49

#### 50 Introduction

Caffeine, a trimethylxanthine, is a ubiquitous socially acceptable drug with no apparent long-51 term health effects.<sup>1</sup> While there is some evidence that caffeine may improve single<sup>2</sup> and 52 repeated sprint activities,<sup>3</sup> effects are most consistently observed in sustained bouts of high-53 intensity aerobic exercise.<sup>1</sup> Typical ergogenic doses of  $3 - 6 \text{ mg} \cdot \text{kg}^{-1}$  ingested 30 - 9054 minutes prior to exercise have been shown to result in performance increases of up to 6% in 55 events lasting from a few minutes to several hours.<sup>1</sup> The key mechanism by which caffeine is 56 believed to exert its effect is via the antagonism of adenosine receptors, leading to increases 57 in neurotransmitter release, motor unit firing rates, and pain suppression.<sup>4</sup> However, the 58 59 ubiquitous nature of adenosine receptors, coupled with their ability to produce differential responses depending on the site of action and the receptor subtype involved, has made it 60 61 difficult to identify the precise mechanisms by which caffeine exerts its ergogenic effect.

62

63 One of the problems with trying to evaluate the mechanisms by which caffeine improves high-intensity endurance performance is that the associated physiological responses are likely 64 to be influenced by the increase in exercise intensity responsible for the increase in 65 performance. Although some studies have attempted to address this problem by including a 66 fixed-intensity submaximal bout of exercise (generally at around 60 - 85% VO<sub>2max</sub>) prior to a 67 performance-based test, often as part of a warm-up or when attempting to simulate the steady 68 state conditions that typically occur in the early stages of endurance events, the results 69 contain some discrepancies. For example, whilst some studies have found no effect of caffeine on minute ventilation ( $\dot{V}_E$ ),<sup>5-11</sup> others have reported a significant increase.<sup>12,13</sup> Similarly, many studies report no effect of caffeine on respiratory exchange ratio (RER),<sup>6,8,9,11,13-23</sup> though some have reported a significant decrease,<sup>10,12,24-26</sup> and one, a 70 71 72 73 significant increase.<sup>5</sup> These discrepancies could easily be attributed to statistical error 74 resulting from the relatively small sample sizes that are typical of these investigations, and 75 have often been criticised.<sup>27,28</sup> The aim of this systematic review and meta-analysis was 76 therefore to investigate the effects of caffeine supplementation on physiological responses to 77 78 submaximal exercise.

79

# 80 Methods

#### 81 Systematic review

The databases of Pubmed, SportDiscus, Science Direct, and Web of Science were searched for peer-reviewed publications (prior to September 2015) containing 'caffeine' in the title and any of the following words in the title or the abstract: 'endurance', 'submaximal', 'aerobic', 'steady state', 'exhaustion', or 'fixed intensity'. Reference lists of those studies that passed the initial screening for potential inclusion in the analysis along with those from relevant review articles<sup>4,27-35</sup> and textbooks<sup>1</sup> were also examined for publications which may have eluded the search of online databases.

89

# 90 Inclusion and exclusion criteria

Studies considered for inclusion in this investigation were limited to those conducted on adult (age:  $\geq 18$  years) humans, which had adopted double-blind, randomised, crossover designs using a standard effective caffeine dose of 3 - 6 mg·kg<sup>-1</sup> administered 30 - 90 minutes prior to exercise. Studies examining combinations of supplements were included in the analysis if the experimental design incorporated a caffeine versus placebo comparison.<sup>5,25</sup> In cases

where studies had investigated the effects of different caffeine doses,<sup>10,13,18,36</sup> the dose closest 96 to the upper limit of the inclusion range was used in the analysis. Exercise intensities were 97 constrained to those required to elicit 60 - 85% VO<sub>2max</sub>, since those intensities span the range 98 typically experienced in prolonged endurance events,<sup>37</sup> and as such, were the most commonly 99 used to evaluate the effects of caffeine on submaximal physiological responses. On those 100 occasions where studies had investigated the effects of caffeine supplementation on several 101 exercise intensities,<sup>19,22,26,36,38</sup> the intensity closest to the middle of the inclusion range was 102 chosen for the analysis. Exercise duration was limited to a minimum of 5 minutes, to provide 103 104 sufficient time for physiological responses to achieve a steady state; and to a maximum of 30 105 minutes to reduce any effect that fatigue may have on the results. Studies using bouts of submaximal exercise longer than 30 minutes were included in the analysis if physiological 106 107 measurements were made within the 5 - 30 minutes inclusion window. In instances where 108 authors had made multiple measurements within the 5 - 30 minutes inclusion window, values 109 closest to the upper limit of 30 minutes were used in the meta-analysis. No inclusion restrictions were placed on potential moderator variables of gender, training status, caffeine 110 111 habituation, or supplementation method, since previous research has failed to establish whether any of those variables influence the effects of caffeine on endurance performance.<sup>1</sup> 112 113 However, subgroup meta-analyses were used to investigate potential influences of 114 supplementation method and exercise intensity on the physiological responses to caffeine (see below). 115

116

#### 117 Data extraction

For the meta-analysis, data were extracted from relevant publications as means, standard deviations (SD), and sample sizes. In instances where data were presented in a graphical format, images were enlarged to improve the precision of the data estimates. Physiological responses were limited to those which were most commonly evaluated during submaximal exercise, which were: heart rate, oxygen uptake ( $\dot{V}O_2$ ), RER,  $\dot{V}_E$ , rating of perceived exertion (RPE), blood lactate concentration [BLa], and blood glucose concentration [BGI]. Measures of RPE were constrained to those evaluated using the 15-point scale.<sup>39</sup>

125

# 126 Meta-analysis

127 From an initial search result of 483 studies, 26 met the inclusion criteria for the meta-analysis (Table 1). Meta-analyses were conducted using specialist software (Review Manager Version 128 129 5.3. The Nordic Cochrane Centre, Copenhagen: The Cochrane Collaboration, 2014). Meta-130 analyses were completed using a random-effects model and data are presented as raw mean 131 difference (D) with associated 95% confidence limits ( $CL_{95}$ ). The choice to use D rather than a standardized mean difference was based on the fact that each physiological response was 132 measured on the same scale.<sup>40</sup> Moreover, the advantage of using D is that it provides an 133 outcome to the analysis which is intuitively meaningful to the reader.<sup>40</sup> Heterogeneity 134 between studies was examined using the  $I^2$  statistic, which describes the percentage of 135 variability in mean difference estimates due to heterogeneity rather than chance. When  $I^2$  was 136 > 25% (25 – 50% represents moderate heterogeneity<sup>41</sup>), a subgroup meta-analysis was 137 completed to investigate the source of heterogeneity. In line with recommendations regarding 138 tests for heterogeneity, <sup>42</sup> CL<sub>95</sub> for  $I^2$  were calculated using the method outlined by Higgins & 139 Thompson.<sup>43</sup> Subgroup meta-analyses were performed, when appropriate, to investigate the 140 influence of the following potential moderator variables: 1) exercise intensity (constrained to 141 142 comparisons between the upper ['high intensity'] and lower ['low intensity'] half of the

143 inclusion range); and 2) supplementation method (capsule versus drink formats). Of the 144 remaining potential moderator variables, no comparisons were made to investigate the effects of: 1) exercise mode: since most had used either cycling (n = 17) or running (n = 5) and there 145 was no rationale to expect any differential effects of caffeine; 2) gender: since only one study 146 (2) had used solely female participants; 3) training status: since between-study inconsistences 147 148 in the way that this variable was reported/measured did not allow quantification with adequate precision; 4) caffeine dose: since most studies (n = 21) had used doses of 5 - 6149 150  $mg kg^{-1}$ ; and 5) administration time: since most studies had administered the supplement 60 minutes prior to exercise (n = 21). Heterogeneity between subgroups was also evaluated 151 using the  $I^2$  statistic. Statistical significance was accepted at p < 0.05 for all analyses. 152

- 153
- 154 Results

#### 155 *Heart rate*

Relative to place by, there was no significant effect of caffeine on heart rate (Figure 1) (D = -156 0.01 b·min<sup>-1</sup>; CL<sub>95</sub>[-1.43, +1.42]; p = 0.99; n = 207). There was a moderate degree of 157 heterogeneity in heart rate responses between the 21 studies included in the analysis ( $I^2$  = 158 27%;  $CL_{95}[0, 57]$ ). Subgroup analyses revealed that there was no evidence of heterogeneity 159 160 between studies performed in the upper half of the exercise intensity inclusion range or 161 between those studies that administered caffeine in a drink format (Table 2). Nevertheless, 162 there were still no effects of caffeine on heart rate, regardless of subgroup, and there was no 163 evidence of heterogeneity between subgroups (Table 2).

164

#### 165 Oxygen uptake

The effects of caffeine on  $\dot{V}O_2$  during submaximal exercise are presented in Figure 2. Relative to placebo, caffeine had no significant effect on  $\dot{V}O_2$  ( $D = -0.00 \text{ L} \cdot \text{min}^{-1}$ ;  $CL_{95}[-0.04, +0.03]$ ; p = 0.92; n = 203) and the level of heterogeneity across the 20 studies that were analysed was low ( $I^2 = 24\%$ ;  $CL_{95}[0, 56]$ ).

170

# 171 Respiratory exchange ratio

172 In comparison with placebo, there was no significant effect of caffeine on RER during 173 submaximal exercise (D = -0.01; CL<sub>95</sub>[-0.01, 0.00]; p = 0.18; n = 181) (Figure 2). There was, 174 however, evidence of high heterogeneity between the 18 studies that were analysed ( $I^2 =$ 175 69%; CL<sub>95</sub>[50, 81]). Evidence of high between-study heterogeneity remained in each of the 176 subgroups analysed (Table 2), but there was no evidence of heterogeneity between subgroups 177 (Table 2).

178

# 179 Minute ventilation

Eight studies measured the effect of caffeine on  $\dot{V}_E$  during submaximal exercise, the effects of which are presented in Figure 2. Relative to placebo, caffeine resulted in a significant increase in  $\dot{V}_E$  ( $D = +3.36 \text{ L}\cdot\text{min}^{-1}$  [+1.63, +5.08]; p = 0.0001; n = 73), and there was no evidence of heterogeneity between studies ( $I^2 = 0\%$ ; CL<sub>95</sub>[0, 68]).

184

# 185 *Rating of perceived exertion*

In comparison with placebo, caffeine resulted in a significant reduction in RPE (D = -0.8 [-186 187 1.1, -0.6]; p < 0.00001; n = 147) during submaximal exercise (Figure 1). There was, however, evidence of moderate heterogeneity between studies (n = 15)  $(l^2 = 35\%; CL_{95}[0, 65])$ . 188 Subgroup analyses revealed that there was no evidence of heterogeneity between studies 189 performed in the lower half of the exercise intensity inclusion range or between studies that 190 191 administered caffeine in a capsule format (Table 2). Nevertheless, there was no evidence of heterogeneity between subgroups and the effect of caffeine on RPE remained regardless of 192 193 any subgroup heterogeneity (Table 2),

194

# 195 *Blood lactate*

The effect of caffeine on [BLa] is presented in Figure 3. Relative to placebo, caffeine resulted in a significant increase in [BLa] ( $D = +0.69 \text{ mmol} \cdot \text{L}^{-1}$  [+0.46, +0.93]; p < 0.00001; n = 208). However, there was evidence of high heterogeneity between the 21 studies that met the inclusion criteria ( $I^2 = 74\%$ ; CL<sub>95</sub>[60, 83]). Evidence of high heterogeneity remained in all subgroup analyses; though the significant effect of caffeine on [BLa] was lost in the subgroup that administered caffeine in a drink format and there was evidence of high heterogeneity between the supplementation method subgroups (Table 2).

203

# 204 Blood glucose

In comparison with placebo, there was a significant increase in [BGI] ( $D = +0.42 \text{ mmol}\cdot\text{L}^{-1}$ [+0.29, +0.55]; p < 0.00001; n = 129) following caffeine supplementation (Figure 3). There was, however, evidence of high heterogeneity between the 15 studies analysed ( $I^2 = 75\%$ ; CL<sub>95</sub>[59, 85]) and there was evidence of heterogeneity in each of the subgroups (Table 2). Nevertheless, the significant effect of caffeine on [BGI] remained in each subgroup, though there was evidence of moderate heterogeneity between the exercise intensity subgroups (Table 2).

212

# 213 Discussion

214 The aim of this study was to carry out a systematic review and meta-analysis of the effects of caffeine supplementation on physiological responses to submaximal exercise. The key 215 216 findings were that caffeine supplementation resulted in significant increases in  $\dot{V}_{F_{s}}$  [BLa], 217 and [BGI]. In contrast, caffeine had a significant suppressive effect on RPE, and no effect on 218 heart rate, RER, or  $\dot{V}O_2$ . Despite similar methodological approaches adopted by the studies 219 included in the meta-analysis, there were several instances of moderate to high heterogeneity; 220 although, in several instances, the confidence limits suggest a large degree of uncertainty in the true magnitude of that heterogeneity. Nevertheless, apart from the [BLa] response in the 221 222 subgroup that administered caffeine in a drink format, the effects of caffeine on the above 223 physiological responses remained regardless of any heterogeneity and the effects of 224 heterogeneity could not be explained by between-study differences in exercise intensity or 225 supplementation method.

226

The key mechanism by which caffeine is believed to interact with human tissue, and thereby influence endurance performance, is via the antagonism of adenosine receptors.<sup>4,31</sup> If this is the case, it should be possible to resolve all of the responses determined in this meta-analysis by that mechanism. Adenosine is a ubiquitous endogenous extracellular signalling molecule,

the concentration of which increases during exercise due to the hydrolysis of adenosine 231 triphosphate.<sup>44,45</sup> Adenosine exerts its effect via its interaction with G-protein coupled cell 232 membrane receptors, widely expressed throughout the body, and of which there are four subtypes (A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub>).<sup>44,45</sup> Although adenosine has the highest affinity for the A<sub>1</sub> and A<sub>2A</sub> receptor subtypes,<sup>45</sup> the ability of adenosine receptors to activate and inhibit the same signalling cascades<sup>44,45</sup> has made it difficult to identify the precise mechanism by which 233 234 235 236 adenosine exerts its effects. Nevertheless, there is evidence that adenosine signalling affects 237 glucose homeostasis and lipid metabolism,<sup>44</sup> central nervous system function,<sup>46</sup> and cardiovascular and respiratory responses;<sup>47</sup> all of which could explain the physiological 238 239 240 responses observed in this meta-analysis.

241

242 During exercise, [BLa] is determined from the balance between lactate production and 243 clearance; with approximately 70 - 80% of the latter achieved via oxidation, and the remainder by gluconeogenesis.<sup>48</sup> As such, the caffeine-induced increase in [BLa] determined 244 in this meta-analysis could be due to either an increase in lactate production (via glycolysis) 245 or an impairment of clearance. Although there is some evidence that adenosine signalling can 246 inhibit glycolysis via a corresponding reduction in insulin sensitivity,<sup>49-51</sup> there is no evidence 247 that caffeine antagonises this response. Indeed, despite an increase in [BLa], Graham et al.<sup>17</sup> 248 249 was unable to detect any effect of caffeine on lactate release from active muscle. Moreover, in a subsequent meta-analysis, Graham et al.<sup>28</sup> found no effect of caffeine on post-exercise 250  $(10 - 15 \text{ mins at } 70-85\% \text{ VO}_{2\text{max}})$  muscle glycogen concentrations. Similar difficulties exist 251 252 when trying to explain the increase in [BLa] by a possible impairment of lactate clearance, in 253 that whilst there is evidence that adenosine signalling increases gluconeogenesis, caffeine does not appear to impair this process; at least not when determined from the rate of post-254 exercise [BLa] clearance.<sup>52</sup> In short, at present, despite a clear effect of caffeine on [BLa] 255 during submaximal exercise, the mechanisms to explain that response remain unresolved. 256

257

As with [BLa], the effects of caffeine on [BGI] can be explained by a mismatch between 258 production and clearance. In the case of clearance, there is evidence that adenosine facilitates 259 intracellular glucose transport, via insulin-dependent and independent mechanisms.53 260 Moreover, while there are likewise many contradictory reports,<sup>44</sup> there is also evidence that 261 caffeine antagonises that response.<sup>54</sup> In contrast, the idea that caffeine may increase [BGI] by 262 facilitating an increase in hepatic glucose release seems much less likely; indeed, there is 263 some evidence that adenosine may even increase hepatic glycogenolysis via A<sub>1</sub> receptor 264 signalling.<sup>44</sup> In short, a caffeine-facilitated impairment of glucose clearance provides the most 265 likely mechanism to explain the increase in [BG] determined in this meta-analysis. 266

267

One finding from this meta-analysis that is particularly difficult to explain is the lack of any 268 effect of caffeine on RER. Goedecke et al.<sup>55</sup> reported a strong positive correlation (r = 0.63) 269 between RER and [BLa] during exercise at 70% VO<sub>2max</sub>. As such, it is surprising that despite 270 271 the fact that caffeine supplementation resulted in a significant increase in [BLa], there was no 272 corresponding increase in RER; in fact, the pattern of the response was towards a reduction in RER. Nevertheless, caffeine did result in an increase in  $\dot{V}_{E,}$  a response which could be 273 explained by the buffering response associated with the disruption of acid-base balance, as 274 indicated by the caffeine-induced increase in [BLa].<sup>56</sup> Then again, it is possible to explain the 275 increase in  $\dot{V}_E$  by a direct stimulatory effect of caffeine, particularly since caffeine is reported 276 to lower the sensitivity threshold of central chemoreceptors for CO<sub>2</sub>;<sup>57</sup> moreover, the fact that 277

adenosine has differential effects on  $\dot{V}_E$  depending on the type of adenosine receptor affected,<sup>58</sup> suggests that the response is most likely due to the effect of caffeine on the A<sub>1</sub> receptor subtype.<sup>58</sup> Either way, given that at least part of the caffeine-induced increase in  $\dot{V}_E$ is likely due to the drive to reduce CO<sub>2</sub>, it is difficult to explain how, in the absence of any corresponding change in  $\dot{V}O_2$ , that response does not affect RER.

283

284 Although this meta-analysis revealed no effect of caffeine on heart rate, it is difficult to 285 reconcile that response with adenosine receptor antagonism, given that adenosine is reported to increase heart rate,<sup>47,59</sup> most likely by reducing parasympathetic and increasing cardiac 286 sympathetic nervous system tone.<sup>59</sup> However, exogenous adenosine infusions have been 287 shown to have differential effects on heart rate depending on the dose and the site of 288 infusion.<sup>47</sup> Moreover, while there is evidence of a small caffeine-induced reduction in resting 289 heart rate,<sup>31,52</sup> that effect is reported to dissipate as exercise intensity increases,<sup>52</sup> supporting the findings of this meta-analysis. Nevertheless, and as previously reported,<sup>30</sup> caffeine did 290 291 lead to a reduction in RPE, a response which could be explained by the fact that adenosine 292 has be shown to increase pain, at least in animal models, and most likely via interaction with 293 A<sub>2B</sub> receptors.<sup>60</sup> However, given that the RPE scale was developed to reflect also the heart rate response to exercise,<sup>39</sup> the findings of this meta-analysis suggest that caffeine may 294 295 296 uncouple that relationship.

297

298 Although the effects of caffeine as an adenosine receptor antagonist can explain most of the 299 effects determined in this meta-analysis, there are instances where, depending on the receptor 300 subtype involved, adenosine can elicit contrasting effects to those highlighted above. 301 However, given the clear effects of caffeine on most of the physiological responses 302 examined, it seems unlikely that those effects are important, at least during the exercise 303 conditions examined in this meta-analysis. Finally, it is worth noting that despite the clear 304 effects of caffeine determined in this meta-analysis, there were many instances where studies 305 were unable to detect those effects, most likely due to issues associated with relatively small 306 sample sizes.

307

# 308 Conclusion

The results of this meta-analysis reveal clear effects of caffeine on [BLa], [BGI],  $V_E$ , and 309 310 RPE during submaximal exercise, independent of any ergogenic response. While those effects can be explained by the antagonistic effects of caffeine on adenosine receptors, 311 312 differential effects of adenosine on the various receptor subtypes make it difficult to identify 313 the precise mechanisms by which adenosine, and therefore caffeine, influences human 314 physiology. Nevertheless, it is envisaged that the results of this meta-analysis will help to 315 distinguish caffeine-induced physiological responses from those associated with 316 corresponding increases in submaximal endurance performance and, as such, help future 317 researchers to identify the most likely mechanisms by which caffeine exerts its ergogenic 318 effect.

319

# 320 *Practical Applications*

The positive effects of caffeine supplementation on endurance performance are wellestablished; particularly when consumed in a dose of  $3 - 6 \text{ mg} \text{kg}^{-1}$  ingested 30 - 90 minutes prior to exercise.<sup>1</sup> Those performance improvements are accompanied by various

physiological responses associated with the corresponding increase in exercise intensity, 324 325 making it difficult to distinguish performance- from caffeine-related effects. This metaanalysis has revealed clear effects of caffeine on measures of [BLa], [BGI], V<sub>E</sub>, and RPE, 326 independent of any ergogenic effect, which, given its dietary prevalence, reinforces the 327 328 importance of caffeine restriction prior to any experimental intervention or physiological 329 profile. For researchers, the results of this meta-analysis reinforce the problems associated with the use of small sample sizes, with several instances where individual investigations 330 failed to find significant effects despite clear evidence to 331 the contrary.

# 332 **References**

- Burke LM, Desbrow B, Spriet L. Caffeine for Sports Performance. Champaign (IL):
   Human Kinetics; 2013.
- 335 2. Glaister M, Muniz-Pumares D, Patterson SD, Foley P, McInnes G. Caffeine
  336 supplementation and peak anaerobic power output. *Eur J Sport Sci.* 2015;15(5):400-6.
- Glaister M, Howatson G, Abraham CS, et al. Caffeine supplementation and multiple
   sprint running performance. *Med Sci Sports Exerc.* 2008;40(10):1835-40.
- 4. Kalmar JM. The influence of caffeine on voluntary muscle activation. *Med Sci Sports Exerc.* 2005;37(12):2113-9.
- 341 5. Acker-Hewitt TL, Shafer BM, Saunders MJ, Goh Q, Luden ND. Independent and
  342 combined effects of carbohydrate and caffeine ingestion on aerobic cycling performance
  343 in the fed state. *Appl Physiol Nutr Metab.* 2012;37(2):276-83.
- Anderson ME, Bruce CR, Fraser SF, et al. Improved 2000-meter rowing performance in competitive oarswomen after caffeine ingestion. *Int J Sport Nutr Exerc Metab.*2000;10(4):464-75.
- 347 7. Bell DG, Jacobs I, Zamecnik J. Effects of caffeine, ephedrine and their combination on
  348 time to exhaustion during high-intensity exercise. *Eur J Appl Physiol Occup Physiol.*349 1998;77(5):427-33.
- Bruce CR, Anderson ME, Fraser SF, et al. Enhancement of 2000-m rowing performance after caffeine ingestion. *Med Sci Sports Exerc*. 2000;32(11):1958-63.
- Casal DC, Leon AS. Failure of caffeine to affect substrate utilisation during prolonged running. *Med Sci Sports Exerc.* 1985;17(1):174-9.
- McClaran SR, Wetter TJ. Low doses of caffeine reduce heart rate during submaximal
   cycle ergometry. *J Int Soc Sports Nutr.* 2007;4(11). doi:10.1186/1550-2783-4-11.
- Tarnopolsky MA, Atkinson SA, MacDougall JD, Sale DG, Sutton JR. Physiological
   responses to caffeine during endurance running in habitual caffeine users. *Med Sci Sports Exerc.* 1989;21(4):418-24.
- 12. Cruz RS, Alves de Aguiar R, Turnes T, et al. Caffeine affects time to exhaustion and
  substrate oxidation during cycling at maximal lactate steady state. *Nutrients*.
  2015;7(7):5254-64.
- 362 13. Jenkins NT, Trilk JL, Singhal A, O'Connor PJ, Cureton KJ. Ergogenic effects of low
  363 doses of caffeine on cycling performance. *Int J Sport Nutr Exerc Metab.* 2008;18(3):328364 42.
- 365 14. Bell DG, McLellan TM. Exercise endurance 1, 3, and 6 h after caffeine ingestion in caffeine users and nonusers. *J Appl Physiol*. 2002;93(4):1227–34.
- 367 15. Black CD, Waddell DE, Gonglach AR. Caffeine's ergogenic effects on cycling:
   368 neuromuscular and perceptual factors. *Med Sci Sports Exerc*. 2015;47(6):1145-58.
- 16. Demura S, Yamada T, Terasawa N. Effect of coffee ingestion on physiological responses
   and ratings of perceived exertion during submaximal endurance exercise. *Percept Mot Skills*. 2007;105(3):1109-16.
- 372 17. Graham TE, Helge JW, MacLean DA, Kiens B, Richter EA. Caffeine ingestion does not alter carbohydrate or fat metabolism in human skeletal muscle during exercise. *J Physiol.* 2000;529(3):837-47.
- 375 18. Graham TE, Spriet LL. Metabolic, catecholamine, and exercise performance responses to
   376 various doses of caffeine. *J Appl Physiol*. 1995;78(3):867-74.
- 377 19. Greer F, Friars D, Graham TE. Comparison of caffeine and theophylline ingestion:
  378 exercise metabolism and endurance. *J Appl Physiol*. 2000;89(5):1837-44.
- 20. Olcina GJ, Timóna R, Muñoz D. Caffeine ingestion effects on oxidative stress in a steady-state test at 75%VO<sub>2max</sub>. *Science & Sports*. 2008;23(2):87-90.

- Roy BD, Bosman MJ, Tarnopolsky MA. An acute oral dose of caffeine does not alter
   glucose kinetics during prolonged dynamic exercise in trained endurance athletes. *Eur J Appl Physiol.* 2001;85(3):280-6.
- Toner MM, Kirkendall DT, Delio DJ, et al. Metabolic and cardiovascular responses to exercise with caffeine. *Ergonomics*. 1982;25(12):1175-83.
- 23. VanSoeren MH, Graham TE. Effect of caffeine on metabolism, exercise endurance, and
   catecholamine responses after withdrawal. *J Appl Physiol*. 1998;85(4):1493–1501.
- 24. Costill DL, Dalsky GP, Fink WJ. Effects of caffeine ingestion on metabolism and
   exercise performance. *Med Sci Sports*. 1978;10(3):155-8.
- 390 25. Giles D, Maclaren D. Effects of caffeine and glucose ingestion on metabolic and
   391 respiratory functions during prolonged exercise. *J Sports Sci.* 1984;2(1):35-46.
- 392 26. Stadheim HK, Kvamme B, Olsen R, et al. Caffeine increases performance in cross393 country double-poling time trial exercise. *Med Sci Sports Exerc*. 2013;45(11):2175-83.
- 27. Graham TE. Caffeine and exercise. *Sports Med.* 2001;31(11):785-807.
- 395 28. Graham TE, Battram DS, Dela F, El-Sohemy A, Thong FSL. Does caffeine alter muscle
  396 carbohydrate and fat metabolism during exercise? *Appl Physiol Nutr Metab.*397 2008;33(6):1311-8.
- 398 29. Burke LM. Caffeine and sports performance. *Appl Physiol Nutr Metab.* 2008;33(6):1319399 34.
- 30. Doherty M, Smith PM. Effects of caffeine ingestion on rating of perceived exertion during and after exercise: a meta-analysis. *Scand J Med Sci Sports*. 2005;15(2):69-78.
- 402 31. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain
  403 with special reference to factors that contribute to its widespread use. *Pharmacol Rev.*404 1999;51(1):83-133.
- 32. Goldstein ER, Ziegenfuss T, Kalman D, et al. International society of sports nutrition
   position stand: caffeine and performance. *J Int Soc Sports Nutr.* 2010;7(1):1-15.
- 407 33. Nehlig A, Debry G. Caffeine and sports activity: a review. Int J Sports Med.
   408 1994;15(5):215-23.
- 34. Tarnopolsky MA. Effect of caffeine on the neuromuscular system-potential as an ergogenic aid. *Appl Physiol Nutr Metab.* 2008;33(6):1284-9.
- 35. Warren GL, Park, ND, Maresca RD, McKibans KI, Millard-Stafford ML. Effect of
  caffeine ingestion on muscular strength and endurance: a meta-analysis. *Med Sci Sports Exerc.* 2010;42(7):1375-87.
- 36. Stadheim HK, Spencer M, Olsen R, Jensen J. Caffeine and Performance over Consecutive
   Days of Simulated Competition. *Med Sci Sports Exerc.* 2014;46(9):1787-96
- 37. Bassett DR, Howley ET. Limiting factors for maximum oxygen uptake and determinants
  of endurance performance. *Med Sci Sports Exerc*. 2000;32(1):70-84.
- 38. Doherty M, Smith PM, Hughes MG, Davison RCR. Caffeine lowers perceptual response
  and increases power output during high-intensity cycling. *J Sports Sci.* 2004:22(7):63743.
- 421 39. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehab Med.
  422 1970;2(2):92-8.
- 423 40. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis.
  424 Chichester, UK: John Wiley & Sons, Ltd.; 2009.
- 425 41. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-426 analyses. *BMJ*. 2003;327:557-60.
- 427 42. Ioannidis JPA, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. *BMJ*. 2007;335:914-6.
- 429 43. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta analysis. *Stat Med.*430 2002;21:1539-58.

- 431 44. Koupenova M, Ravid K. Adenosine, adenosine receptors and their role in glucose
  432 homeostasis and lipid metabolism. *J Cell Physiol*. 2013; doi:10.1002/jcp.24352.
- 433 45. Layland J, Carrick D, Lee M, Oldroyd K, Berry C. Adenosine: physiology, 434 pharmacology, and clinical applications. *JACC: Cardiovasc Interv.* 2014;7(6):581-91.
- 435 46. Benarroch EE. Adenosine and its receptors: multiple modulatory functions and potential
  436 therapeutic targets for neurologic disease. *Neurology*. 2008;70(3):231-6.
- 437 47. Biaggioni I, Olafsson B, Robertson RM, Hollister AS, Robertson D. Cardiovascular and
   438 respiratory effects of adenosine in conscious man: evidence for chemoreceptor activation.
   439 *Circ Res.* 1987;61(6):779-86.
- 440 48. Bergman BC, Horning MA, Casazza GA, et al. Endurance training increases
  441 gluconeogenesis during rest and exercise in men. *Am J Physiol Endocrinol Metab.*442 2000;278(2):E244-51.
- 443 49. Budohoski L, Challiss RA, McManus B, Newsholme EA. Effects of analogues of
  444 adenosine and methyl xanthines on insulin sensitivity in soleus muscle of the rat. *FEBS*445 *Lett.* 1984;167(1):1-4.
- 50. Challis RA, Budohoski L, McManus B, Newsholme EA. Effects of an adenosine-receptor
  antagonist on insulin-resistance in soleus muscle from obese Zucker rats. *Biochem J*.
  1984;221(3):915-7.
- 51. Espinal J, Challiss RA, Newsholme EA. Effect of adenosine deaminase and an adenosine
  analogue on insulin sensitivity in soleus muscle of the rat. *FEBS Lett.* 1983;158(1):103-6.
- 451 52. Glaister M, Williams BH, Muniz-Pumares D, Balsalobre-Fernández C, Foley P. The
  452 Effects of caffeine supplementation on physiological responses to submaximal exercise in
  453 endurance-trained men. *PLoS One.* 2016;11(8):e0161375.
- 454 53. Angello DA, Berne RM, Coddington NM. Adenosine and insulin mediate glucose uptake
  455 in normoxic rat hearts by different mechanisms. *Am J Physiol*. 1993;265(3):H880-5.
- 456 54. Thong FSL, Derave W, Kiens B, et al. Caffeine-induced impairment of insulin action but
  457 not insulin signaling in human skeletal muscle is reduced by exercise. *Diabetes*.
  458 2002;51(3):583-90.
- 55. Goedecke JH, St Clair Gibson A, Grobler L, et al. Determinants of the variability in
  respiratory exchange ratio at rest and during exercise in trained athletes. *Am J Physiol Endocrinol Metab.* 2000;279(6):E1325-34.
- 462 56. Péronnet F, Aguilaniu B. Lactic acid buffering, nonmetabolic CO<sub>2</sub> and exercise
  463 hyperventilation: a critical reappraisal. *Respir Physiol Neurobiol*. 2006;150(1):4-18.
- 464 57. Howell LL, Coffin VL, Spealman RD. Behavioral and physiological effects of xanthines
   465 in nonhuman primates. *Psychopharmacology*. 1997;129(1):1-14.
- 58. Lahiri S, Mitchell CH, Reigada D, Roy A, Cherniack NS. Purines, the carotid body and
  respiration. *Respir Physiol Neurobiol*. 2007;157(1):123–9.
- 468 59. Rongen GA, Brooks SC, Pollard MJ, et al. Effect of adenosine on heart rate variability in humans. *Clin Sci.* 1999;96(6):597-604.
- 60. Hu X, Adebiyi MG, Luo J, et al. Sustained elevated adenosine via ADORA2B promotes
  chronic pain through neuro-immune Interaction. *Cell Rep.* 2016;16(1):106-19.
- 472 61. Daniels JW, Molé PA, Shaffrath JD, Stebbins CI. Effects of caffeine on blood pressure,
  473 heart rate, and forearm blood flow during dynamic leg exercise. *J Appl Physiol*.
  474 1998;85(1):154–9.
- 475 62. Graham TE, Hibbert E, Sathasivam P. Metabolic and exercise endurance effects of coffee
  476 and caffeine ingestion. *J Appl Physiol*. 1998;85(3):883–9.
- 477

#### 478 Figure Legends

**Figure 1.** Forest plots of studies that have investigated the effects of caffeine supplementation on heart rate (upper plot) and ratings of perceived exertion (lower plot) during sustained (5 – 30 minutes) fixed-intensity (60 - 85%  $\dot{V}O_{2max}$ ) submaximal exercise. Squares represent the raw mean difference, relative to placebo, with associated 95% confidence limits. The size of each square reflects the weighting given to the response. The diamond at the base of each plot represents the overall effect calculated from a random effects model; the width of the diamond representing the 95% confidence interval.

486

487 Figure 2. Forest plots of studies that have investigated the effects of caffeine 488 supplementation on oxygen uptake (upper plot), respiratory exchange ratio (middle plot), and minute ventilation (lower plot) during sustained (5 - 30 minutes) fixed-intensity (60 - 85%)489 490  $\dot{V}O_{2max}$ ) submaximal exercise. Squares represent the raw mean difference, relative to placebo, with associated 95% confidence limits. The size of each square reflects the weighting given 491 to the response. The diamond at the base of each plot represents the overall effect calculated 492 493 from a random effects model; the width of the diamond representing the 95% confidence 494 interval.

495

**Figure 3.** Forest plots of studies that have investigated the effects of caffeine supplementation on blood lactate (upper plot) and blood glucose (lower plot) concentrations during sustained (5 – 30 minutes) fixed-intensity (60 - 85%  $\dot{V}O_{2max}$ ) submaximal exercise. Squares represent the raw mean difference, relative to placebo, with associated 95% confidence limits. The size of each square reflects the weighting given to the response. The diamond at the base of each plot represents the overall effect calculated from a random effects model; the width of the diamond representing the 95% confidence interval.

**Table 1**. The effects of caffeine supplementation (3-6 mg·kg<sup>-1</sup>), administered 30 – 90 minutes prior to a sustained ( $\geq$  5 minutes) fixed-intensity bout of submaximal (60 – 85%  $\dot{VO}_{2max}$ ) exercise, on selected physiological responses.

| Author(s)                         | n             | Exercise<br>mode | Exercise duration and<br>intensity | Training status | Gender | Dose (mg∙kg <sup>-1</sup> ) | Pre-test supplementation<br>time (mins) | Supplementation<br>method | * Physiological responses   |
|-----------------------------------|---------------|------------------|------------------------------------|-----------------|--------|-----------------------------|---|---------------------------|---|
| Acker-Hewitt et al.⁵              | 10            | Cycling          | 20 mins @ 60% VO <sub>2max</sub>   | Cyclists        | М      | 6                           | 60                                      | Capsule                   | $\uparrow$ RER; no $\Delta$ in [BGI], [BLa], HR, RPE, $\dot{V}_{E}$ , or $\dot{V}O_{2}$                   |
| Anderson et al. <sup>6</sup>      | 8             | Rowing           | 6 mins @ ~74% VO <sub>2max</sub>   | Rowers          | F      | 6                           | 60                                      | Capsule                   | no $\Delta$ in [BLa], HR, RER, RPE, $\dot{V}_{E}$ , or $\dot{V}O_{2}$                                     |
| Bell & McLellan <sup>14</sup>     | 13            | Cycling          | 80% VO <sub>2max</sub> to exh      | Active          | M&F    | 5                           | 60                                      | Capsule                   | ↑ $[BGI]^{\dagger\dagger}$ , $[BLa]^{\dagger\dagger}$ , HR, & VO <sub>2</sub> ; ↓ RPE; no $\Delta$ in RER |
| Bell & McLellan <sup>14</sup>     | $8^{\dagger}$ | Cycling          | 80% VO <sub>2max</sub> to exh      | Active          | M&F    | 5                           | 60                                      | Capsule                   | ↑ [BGI], [BLa], HR, & $\dot{V}O_2; \downarrow$ RPE; no $\Delta$ in RER                                    |
| Bell et al. <sup>7</sup>          | 8             | Cycling          | 85% VO <sub>2max</sub> to exh      | Healthy         | М      | 5                           | 90                                      | Capsule                   | $\uparrow$ [BLa] , no $\Delta$ in [BGI], HR, RPE, $\dot{V}_{E}$ , or $\dot{VO}_{2}$                       |
| Black et al. <sup>15</sup>        | 14            | Cycling          | 30 mins @ 60% VO <sub>2max</sub>   | Active          | M&F    | 5                           | 60                                      | Capsule                   | $\uparrow$ [BLa]; no $\Delta$ in HR, RPE, RER, or $\dot{ m VO}_2$   |
| Black et al. <sup>15</sup>        | 14            | Arm cranking     | 30 mins @ 60% VO <sub>2max</sub>   | Active          | M&F    | 5                           | 60                                      | Capsule                   | $\uparrow$ [BLa]; no $\Delta$ in HR, RPE, RER, or $\dot{ m VO}_2$   |
| Bruce et al. <sup>8</sup>         | 8             | Rowing           | 6 mins @ 75% VO <sub>2max</sub>    | Rowers          | М      | 6                           | 60                                      | Capsule                   | no $\Delta$ in HR, RER, RPE, $\dot{V}_{E}$ , or $\dot{V}O_{2}$  |
| Casal & Leon <sup>9</sup>         | 9             | Running          | 45 mins @ 75% VO <sub>2max</sub>   | Runners         | М      | ~6 (400 mg)                 | 60                                      | Drink <sup>‡</sup>        | no $\Delta$ in HR, RER, RPE, $\dot{V}_{E}$ , or $\dot{V}O_{2}$  |
| Costill et al. <sup>24</sup>      | 9             | Cycling          | 80% VO <sub>2max</sub> to exh      | Cyclists        | M&F    | ~5 (330 mg)                 | 60                                      | Drink <sup>‡</sup>        | $\downarrow$ RER & RPE; no $\Delta$ in [BGI], [BLa], HR, or $\dot{ m VO}_2$                               |
| Cruz et al. <sup>12</sup>         | 8             | Cycling          | ~73% VO <sub>2max</sub> to exh     | Active          | м      | 6                           | 60                                      | Capsule                   | $\uparrow$ [BGI], [BLa], $\dot{V}_{ m E}; \downarrow$ RER; no $\Delta$ in HR, or $\dot{V}{ m O}_2$        |
| Daniels et al.61                  | 10            | Cycling          | 55 mins @ 65% VO <sub>2max</sub>   | Cyclists        | M&F    | 6                           | 45                                      | Capsule                   | no $\Delta$ in HR   |
| Demura et al. <sup>16</sup>       | 10            | Cycling          | 60 mins @ 60% VO <sub>2max</sub>   | Healthy         | М      | 6                           | 60                                      | Drink <sup>‡</sup>        | $\downarrow$ RPE; no $\Delta$ in [BLa], HR, RER, or $\dot{ m VO}_2$                                       |
| Doherty et al. <sup>38</sup>      | 11            | Cycling          | 6 mins @ 70% VO <sub>2max</sub>    | Cyclists        | М      | 5                           | 60                                      | Drink <sup>**</sup>       | no $\Delta$ in HR or RPE  |
| Giles & Maclaren <sup>25</sup>    | 6             | Running          | 120 mins @ 65% VO <sub>2max</sub>  | Runners         | М      | 5                           | 60                                      | Drink <sup>‡</sup>        | ↑ $\dot{V}O_2$ ; ↓ RER & RPE; no $\Delta$ in [BGI], or [BLa]  |
| Graham & Spriet <sup>18</sup>     | 8             | Running          | 85% VO <sub>2max</sub> to exh      | Runners         | М      | 6                           | 60                                      | Capsule                   | $\uparrow$ [BGI]; no $\Delta$ in [BLa], RER, or $\dot{VO}_{2}$  |
| Graham et al. <sup>62</sup>       | 9             | Running          | 85% VO <sub>2max</sub> to exh      | Runners         | M&F    | 4.45                        | 60                                      | Capsule                   | no $\Delta$ in [BGI] or [BLa]   |
| Graham et al. <sup>62</sup>       | 9             | Running          | 85% VO <sub>2max</sub> to exh      | Runners         | M&F    | 4.45                        | 60                                      | Drink <sup>‡</sup>        | no $\Delta$ in [BGI] or [BLa]   |
| Graham et al. <sup>17</sup>       | 10            | Cycling          | 60 mins @ 70% VO <sub>2max</sub>   | Healthy         | М      | 6                           | 60                                      | Capsule                   | $\uparrow$ [BGI] & [BLa],; no $\Delta$ in HR, RER, or $\dot{VO}_2$  |
| Greer et al. <sup>19</sup>        | 7             | Cycling          | 45 mins @ 70% VO <sub>2max</sub>   | Active          | М      | 6                           | 90                                      | Capsule                   | no $\Delta$ in [BGI], [BLa], RER, or $\dot{ m VO}_2$  |
| Jenkins et al.13                  | 13            | Cycling          | 15 mins @ 80% VO <sub>2max</sub>   | Cyclists        | М      | 3                           | 60                                      | Capsule                   | ↑ [BLa] & $\dot{V}_{E}$ ; no $\Delta$ in HR, RER, or $\dot{VO}_{2}$                                       |
| McClaran & Wetter <sup>10</sup>   | 9             | Cycling          | 5 mins @ ~63% VO <sub>2max</sub>   | Active          | М      | 3                           | 30                                      | Capsule                   | $\downarrow$ HR & RER; no $\Delta$ in RPE, $\dot{V}_{E}$ , or $\dot{V}O_{2}$                              |
| Olcina et al. <sup>20</sup>       | 20            | Cycling          | 30 mins @ 75% VO <sub>2max</sub>   | Untrained       | М      | 5                           | 60                                      | Capsule                   | no $\Delta$ in [BLa], RER, or $\dot{VO}_2$  |
| Roy et al. <sup>21</sup>          | 12            | Cycling          | 60 mins @ 65% VO <sub>2max</sub>   | Trained         | M&F    | 6                           | 75                                      | Capsule                   | $\uparrow$ [BLa]; no $\Delta$ in [BGI], HR, RER, or $\dot{V}O_2$  |
| Stadheim et al. <sup>26</sup>     | 10            | X-C skiing       | 5 mins @ 70% VO <sub>2max</sub>    | X-C skiers      | М      | 6                           | ~60                                     | Drink <sup>**</sup>       | ↑ [BGI]; ↓ RER & RPE; no $\Delta$ in [BLa], HR, or $\dot{V}O_2$   |
| Stadheim et al. <sup>36</sup>     | 8             | X-C skiing       | 5 mins @ 65% VO <sub>2max</sub>    | X-C skiers      | М      | 4.5                         | ~60                                     | Drink <sup>**</sup>       | ↑ [BLa]; $\downarrow$ RPE; no $\Delta$ in HR, or $\dot{V}$ O <sub>2</sub>                                 |
| Tarnopolsky et al. <sup>11</sup>  | 6             | Running          | 90 mins @ 70% VO <sub>2max</sub>   | Runners         | М      | 6                           | 60                                      | Drink**                   | no $\Delta$ in [BGI], [BLa], HR, RER, RPE, $\dot{V}_{E}$ , or $\dot{V}O_{2}$                              |
| Toner et al. <sup>22</sup>        | 8             | Cycling          | 5 mins @ 73.2% VO <sub>2max</sub>  | Mixed           | М      | ~4.6 (350 mg)               | 60                                      | Drink <sup>‡</sup>        | no $\Delta$ in HR, RER, or $\dot{V}O_2$   |
| Van Soeren & Graham <sup>23</sup> | 6             | Cycling          | 85% VO <sub>2max</sub> to exh      | Active          | М      | 6                           | 60                                      | Capsule                   | no $\Delta$ in [BGI], [BLa], RER, or $\dot{\sf VO}_2$   |

**Note**: [BGI] = blood glucose concentration; [BLa] = blood lactate concentration; HR = heart rate; RER = respiratory exchange ratio; RPE = rating of perceived exertion;  $\dot{V}_E$  = minute ventilation;  $\dot{V}O_2$  = rate of oxygen consumption;  $\dot{V}O_{2max}$  = maximal rate of oxygen consumption; exh = exhaustion; X-C = cross country; M = male; F = female;  $\uparrow$  = significant (p < 0.05) increase relative to placebo;  $\downarrow$  = significant (p < 0.05) decrease relative to placebo; no  $\Delta$  = no significant ( $p \ge 0.05$ ) change relative to placebo;\* = all measurements made within the first 30 minutes of exercise; † = caffeine naive; ‡ = dose added to decaffeinated coffee; \*\* = dose added to artificially sweetened water/lemonade/juice; †† = based on a sample size of 11;

**Table 2**. Summary of subgroup meta-analyses examining the possible influence of exercise intensity (low intensity:  $60 - 72.5\% \dot{V}O_{2max}$  vs high intensity:  $72.5 - 85\% \dot{V}O_{2max}$ ) and supplementation method (capsule vs drink formats) on the effect of caffeine supplementation on various physiological responses during fixed-intensity ( $60 - 85\% \dot{V}O_{2max}$ ) submaximal exercise.

| Parpansas                             | No of studios | Sampla ciza | Maan difforance      |           | Hotorogonaity $l^2$ (%) | Subgroup differences      |      |  |
|---------------------------------------|---------------|-------------|----------------------|-----------|-------------------------|---------------------------|------|--|
| Responses                             | NO OF Studies | Sample Size | Wean unrerence       | μ         | Heterogeneity 7 (%)     | <i>I</i> <sup>2</sup> (%) | p    |  |
| Heart rate (b.min <sup>-1</sup> )     |               |             |                      |           |                         |                           |      |  |
| Low intensity                         | 13            | 132         | -0.57 [-2.81, +1.68] | 0.62      | 47 [0, 72]              | 0                         | 0.22 |  |
| High intensity                        | 8             | 75          | +0.83 [-0.88, +2.54] | 0.34      | 0 [0, 68]               | 0                         | 0.55 |  |
| Capsule                               | 14            | 145         | -0.02 [-2.08, +2.03] | 0.98      | 45 [0, 71]              | 0                         | 0.70 |  |
| Drink                                 | 7             | 62          | -0.40 [-2.38, +1.58] | 0.69      | 0 [0, 71]               | 0                         | 0.79 |  |
| Respiratory exchange ratio            |               |             |                      |           |                         |                           |      |  |
| Low intensity                         | 11            | 109         | -0.00 [-0.02, +0.01] | 0.58      | 67 [38, 83]             | 0                         | 0.02 |  |
| High intensity                        | 7             | 72          | -0.01 [-0.02, 0.00]  | 0.32      | 64 [18, 84]             | 0                         | 0.92 |  |
| Capsule                               | 12            | 132         | -0.00 [-0.01, +0.01] | 0.42      | 50 [3 <i>,</i> 74]      | 0                         | 0.57 |  |
| Drink                                 | 6             | 49          | -0.01 [-0.03, +0.01] | 0.27      | 84 [67, 92]             | 0                         | 0.57 |  |
| Ratings of perceived exertion         |               |             |                      |           |                         |                           |      |  |
| Low intensity                         | 9             | 92          | -0.8 [-1.0, -0.6]    | < 0.00001 | 0 [0, 65]               | 0                         | 0.70 |  |
| High intensity                        | 6             | 55          | -0.9 [-1.6, -0.2]    | 0.02      | 64 [13, 85]             | 0                         | 0.78 |  |
| Capsule                               | 8             | 84          | -0.8 [-1.1, -0.4]    | 0.0001    | 0 [0, 68]               | 0                         | 0.65 |  |
| Drink                                 | 7             | 63          | -0.9 [-1.2, -0.5]    | < 0.00001 | 0.00001 59 [5, 82]      |                           | 0.65 |  |
| Blood lactate (mmol·L <sup>-1</sup> ) |               |             |                      |           |                         |                           |      |  |
| Low intensity                         | 12            | 116         | +0.64 [+0.40, +0.88] | < 0.00001 | 64 [33, 81]             | 0                         | 0.70 |  |
| High intensity                        | 9             | 92          | +0.76 [+0.22, +1.30] | 0.006     | 83 [69, 91]             | 0                         | 0.70 |  |
| Capsule                               | 15            | 159         | +0.87 [+0.62, +1.12] | < 0.00001 | 55 [19, 75]             | 00                        | 0.02 |  |
| Drink                                 | 6             | 49          | +0.33 [-0.07, +0.73] | 0.11      | 82 [62, 92]             | 80                        | 0.02 |  |
| Blood glucose (mmol·L⁻¹)              |               |             |                      |           |                         |                           |      |  |
| Low intensity                         | 7             | 62          | +0.32 [+0.15, +0.49] | 0.0002    | 72 [39, 87]             | 40                        | 0.16 |  |
| High intensity                        | 8             | 67          | +0.51 [+0.31, +0.71] | < 0.00001 | 68 [33, 85]             | 49                        | 0.10 |  |
| Capsule                               | 11            | 98          | +0.42 [+0.25, +0.59] | < 0.00001 | 78 [61, 88]             | 0                         | 0.00 |  |
| Drink                                 | 4             | 31          | +0.40 [+0.20, +0.60] | 0.0001    | 41 [0, 80]              | U                         | 0.90 |  |

Note: Values in square parentheses represent 95% confidence limits

|  | Ca        | affein                         | е        | PI    | acebo  | )        |        | Mean Difference        | Mean Difference    |
|--|-----------|--------------------------------|----------|-------|--------|----------|--------|------------------------|--------------------|
| Study or Subgroup                      | Mean      | SD                             | Total    | Mean  | SD     | Total    | Weight | IV, Random, 95% CI     | IV, Random, 95% CI |
| Acker-Hewitt et al. (2012)             | 140       | 6                              | 10       | 146   | 8      | 10       | 4.2%   | -6.00 [-12.20, 0.20]   |                    |
| Anderson et al. (2000)                 | 153       | 9                              | 8        | 152   | 6      | 8        | 3.1%   | 1.00 [-6.50, 8.50]     |                    |
| Bell & McLellan (2002)                 | 169       | 10                             | 13       | 167   | 8      | 13       | 3.5%   | 2.00 [-4.96, 8.96]     |                    |
| Bell & McLellan (2002)                 | 174       | 8                              | 8        | 172   | 10     | 8        | 2.3%   | 2.00 [-6.87, 10.87]    |                    |
| Bell et al. (1998)                     | 181       | 9                              | 8        | 177   | 10     | 8        | 2.1%   | 4.00 [-5.32, 13.32]    | <b>-</b>           |
| Black et al. (2015)                    | 156       | 11                             | 14       | 161   | 7      | 14       | 3.6%   | -5.00 [-11.83, 1.83]   | <b>-</b>           |
| Black et al. (2015)                    | 146       | 12                             | 14       | 141   | 10     | 14       | 2.7%   | 5.00 [-3.18, 13.18]    |                    |
| Bruce et al. (2000)                    | 161       | 11                             | 8        | 159   | 8      | 8        | 2.1%   | 2.00 [-7.43, 11.43]    |                    |
| Casal & Leon (1985)                    | 149.8     | 8.1                            | 9        | 149.1 | 8.1    | 9        | 3.1%   | 0.70 [-6.78, 8.18]     |                    |
| Cruz et al. (2015)                     | 161.9     | 3.6                            | 8        | 163.5 | 3.1    | 8        | 9.9%   | -1.60 [-4.89, 1.69]    |                    |
| Daniels et al. (1998)                  | 132.5     | 13.9                           | 10       | 146   | 10.9   | 10       | 1.6%   | -13.50 [-24.45, -2.55] |                    |
| Demura et al. (2007)                   | 146.7     | 10.8                           | 10       | 144.1 | 9.3    | 10       | 2.3%   | 2.60 [-6.23, 11.43]    |                    |
| Doherty et al. (2004)                  | 141       | 18                             | 11       | 146   | 12     | 11       | 1.2%   | -5.00 [-17.78, 7.78]   |                    |
| Graham et al. (2000)                   | 158       | 4                              | 10       | 154   | 4      | 10       | 9.3%   | 4.00 [0.49, 7.51]      |                    |
| Jenkins et al. (2008)                  | 181       | 3.4                            | 13       | 179   | 3.1    | 13       | 12.8%  | 2.00 [-0.50, 4.50]     | +                  |
| McClaran & Wetter (2007)               | 146       | 3.5                            | 9        | 148   | 4      | 9        | 9.4%   | -2.00 [-5.47, 1.47]    |                    |
| Roy et al. (2001)                      | 146       | 11                             | 12       | 145   | 11     | 12       | 2.3%   | 1.00 [-7.80, 9.80]     |                    |
| Stadheim et al. (2013)                 | 156       | 4                              | 10       | 156   | 3      | 10       | 10.5%  | 0.00 [-3.10, 3.10]     |                    |
| Stadheim et al. (2014)                 | 142.7     | 3.4                            | 8        | 144.6 | 3.4    | 8        | 9.8%   | -1.90 [-5.23, 1.43]    |                    |
| Tarnopolsky et al. (1989)              | 157.3     | 6.5                            | 6        | 153.3 | 7.7    | 6        | 2.7%   | 4.00 [-4.06, 12.06]    |                    |
| Toner et al. (1982)                    | 152       | 12                             | 8        | 153   | 10     | 8        | 1.6%   | -1.00 [-11.82, 9.82]   |                    |
|  |           |                                |          |       |        |          |        |                        |                    |
| Total (95% CI)                         |           |                                | 207      |       |        | 207      | 100.0% | -0.01 [-1.43, 1.42]    | •                  |
| Heterogeneity: Tau <sup>2</sup> = 2.53 | ; Chi² =  | 27.22                          | , df = 2 | 0 (P= | 0.13); | l² = 27° | %      | -                      |                    |
| Test for overall effect: Z = 0         | ).01 (P = | Favors Placebo Favors Caffeine |          |       |        |          |        |                        |                    |
|  |           |                                |          |       |        |          |        |                        |                    |

|   | Caff       | eine                           | Pla  | aceb | 0     |        | Mean Difference      | Mean Difference    |
|---|------------|--------------------------------|------|------|-------|--------|----------------------|--------------------|
| Study or Subgroup                       | Mean S     | D Tota                         | Mean | SD   | Total | Weight | IV, Random, 95% CI   | IV, Random, 95% CI |
| Acker-Hewitt et al. (2012)              | 11.3 1     | .4 10                          | 11.7 | 0.8  | 10    | 4.8%   | -0.40 [-1.40, 0.60]  |                    |
| Anderson et al. (2000)                  | 11.1 1     | .9 8                           | 10.8 | 1.3  | 8     | 2.2%   | 0.30 [-1.30, 1.90]   |                    |
| Bell & McLellan (2002)                  | 15.4 1     | .3 8                           | 16.8 | 0.8  | 8     | 4.4%   | -1.40 [-2.46, -0.34] |                    |
| Bell & McLellan (2002)                  | 16.2 1     | .4 13                          | 17   | 2    | 13    | 3.0%   | -0.80 [-2.13, 0.53]  | <b>-</b>           |
| Black et al. (2015)                     | 12.6 1     | .3 14                          | 14.1 | 1.2  | 14    | 5.4%   | -1.50 [-2.43, -0.57] |                    |
| Black et al. (2015)                     | 13.4       | 1 14                           | 14   | 1.4  | 14    | 5.7%   | -0.60 [-1.50, 0.30]  |                    |
| Bruce et al. (2000)                     | 10.8 2     | .4 8                           | 11.2 | 2.5  | 8     | 1.0%   | -0.40 [-2.80, 2.00]  |                    |
| Casal & Leon (1985)                     | 11.7 0     | .5 9                           | 12.1 | 0.5  | 9     | 12.8%  | -0.40 [-0.86, 0.06]  |                    |
| Costill et al. (1978)                   | 12.1 0     | .8 9                           | 14.1 | 1    | 9     | 6.3%   | -2.00 [-2.84, -1.16] |                    |
| Demura et al. (2007)                    | 15 1       | .3 10                          | 15.6 | 1.2  | 10    | 4.2%   | -0.60 [-1.70, 0.50]  |                    |
| Doherty et al. (2004)                   | 12.5 1     | .3 11                          | 12.7 | 1.6  | 11    | 3.5%   | -0.20 [-1.42, 1.02]  |                    |
| Giles & MacLaren (1984)                 | 10.5 0     | .6 6                           | 11.7 | 0.5  | 6     | 9.3%   | -1.20 [-1.82, -0.58] | _ <b>-</b>         |
| McClaran & Wetter (2007)                | 13.4       | 1 9                            | 13.8 | 0.9  | 9     | 5.9%   | -0.40 [-1.28, 0.48]  |                    |
| Stadheim et al. (2013)                  | 14.1 0     | .3 10                          | 14.8 | 0.3  | 10    | 18.3%  | -0.70 [-0.96, -0.44] | -                  |
| Stadheim et al. (2014)                  | 11.8 0     | .4 8                           | 12.8 | 0.5  | 8     | 13.2%  | -1.00 [-1.44, -0.56] | _ <b></b>          |
| Total (95% CI)                          |            | 147                            |      |      | 147   | 100.0% | -0.82 [-1.07, -0.58] | •                  |
| Heterogeneity: Tau <sup>2</sup> = 0.07; | Chi² = 21  | -                              |      |      |       |        |                      |                    |
| Test for overall effect: Z = 6          | .53 (P < 0 | -2 -1 U 1 2                    |      |      |       |        |                      |                    |
|   | •          | Favors Placebo Favors Cattelne |      |      |       |        |                      |                    |

| Study or Subgroup         Mean         SD         Total         Mean         SD         Total         Weight         IV, Random, 95% Cl         IV, Random, 95% Cl           Acker-Hewitt et al. (2012)         3.23         0.4         10         3.41         0.36         10         1.0%         -0.18 [-0.51, 0.15]   |
|---|
| Acker-Hewitt et al. (2012)       3.23       0.4       10       3.41       0.36       10       1.0%       -0.18 [-0.51, 0.15]         Anderson et al. (2000)       2.3       0.41       8       2.2       0.94       8       0.2%       0.10 [-0.61, 0.81]         Bell & McLellan (2002)       3.1       0.9       8       3.01       0.73       8       0.2%       0.09 [-0.71, 0.89]         Bell & McLellan (2002)       3.44       0.71       13       3.39       0.75       13       0.4%       0.05 [-0.51, 0.61] |
| Anderson et al. (2000)       2.3       0.41       8       2.2       0.94       8       0.2%       0.10 [-0.61, 0.81]         Bell & McLellan (2002)       3.1       0.9       8       3.01       0.73       8       0.2%       0.09 [-0.71, 0.89]         Bell & McLellan (2002)       3.44       0.71       13       3.39       0.75       13       0.4%       0.05 [-0.51, 0.61]  |
| Bell & McLellan (2002)         3.1         0.9         8         3.01         0.73         8         0.2%         0.09 [-0.71, 0.89]           Bell & McLellan (2002)         3.44         0.71         13         3.39         0.75         13         0.4%         0.05 [-0.51, 0.61]   |
| Bell & McLellan (2002) 3.44 0.71 13 3.39 0.75 13 0.4% 0.05 [-0.51, 0.61]  |
|   |
| Bell et al. (1998) 3.27 0.34 8 3.28 0.41 8 0.8% -0.01 [-0.38, 0.36]   |
| Black et al. (2015) 1.88 0.22 14 1.89 0.27 14 3.1% -0.01 [-0.19, 0.17]  |
| Black et al. (2015) 1.39 0.28 14 1.37 0.28 14 2.5% 0.02 [-0.19, 0.23]   |
| Bruce et al. (2000) 3.56 0.31 8 3.51 0.39 8 0.9% 0.05 [-0.30, 0.40]   |
| Casal & Leon (1985) 2.93 0.06 9 2.97 0.06 9 15.9% -0.04 [-0.10, 0.02]   |
| Costill et al. (1978) 3.34 0.18 9 3.24 0.15 9 4.2% 0.10 [-0.05, 0.25]   |
| Cruz et al. (2015) 2.72 0.12 8 2.72 0.13 8 6.1% 0.00 [-0.12, 0.12]  |
| Demura et al. (2007) 1.95 0.33 10 1.87 0.35 10 1.3% 0.08 [-0.22, 0.38]  |
| Graham et al. (2000) 3.14 0.08 10 3.11 0.09 10 11.9% 0.03 [-0.04, 0.10]   |
| Jenkins et al. (2008) 3.84 0.05 13 3.78 0.05 13 20.2% 0.06 [0.02, 0.10]   |
| McClaran & Wetter (2007) 2.66 0.27 9 2.58 0.27 9 1.8% 0.08 [-0.17, 0.33]  |
| Olcina et al.(2008) 2.26 0.47 20 2.26 0.53 20 1.2% 0.00 [-0.31, 0.31]   |
| Stadheim et al. (2013) 3.18 0.07 10 3.28 0.14 10 8.5% -0.10 [-0.20, -0.00]  |
| Stadheim et al. (2014) 3.13 0.08 8 3.19 0.06 8 12.9% -0.06 [-0.13, 0.01]  |
| Tarnopolsky et al. (1989) 4.44 0.21 6 4.31 0.15 6 2.5% 0.13 [-0.08, 0.34]   |
| Toner et al. (1982) 2.96 0.15 8 3.05 0.15 8 4.5% -0.09 [-0.24, 0.06]  |
| Total (95% CI) 203 203 100.0% -0.00 [-0.04, 0.03]   |
| Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 25.17, df = 19 (P = 0.16); l <sup>2</sup> = 24%  |
| -0.5 -0.25 0 0.25 0.5   |

|   | -        |        |         |          |         |         |        |                       |                                |
|---|----------|--------|---------|----------|---------|---------|--------|-----------------------|--------------------------------|
|   | Ca       | affein | е       | P        | lacebo  |         |        | Mean Difference       | Mean Difference                |
| Study or Subgroup                         | Mean     | SD     | Total   | Mean     | SD      | Total   | Weight | IV, Random, 95% CI    | IV, Random, 95% CI             |
| Acker-Hewitt et al. (2012)                | 0.96     | 0.07   | 10      | 0.89     | 0.03    | 10      | 2.7%   | 0.07 [0.02, 0.12]     | — •—                           |
| Anderson et al. (2000)                    | 0.84     | 0.04   | 8       | 0.89     | 0.06    | 8       | 2.5%   | -0.05 [-0.10, -0.00]  |                                |
| Black et al. (2015)                       | 0.97     | 0.06   | 14      | 0.96     | 0.07    | 14      | 2.6%   | 0.01 [-0.04, 0.06]    |                                |
| Black et al. (2015)                       | 0.94     | 0.03   | 14      | 0.93     | 0.05    | 14      | 4.9%   | 0.01 [-0.02, 0.04]    |                                |
| Bruce et al. (2000)                       | 0.94     | 0.09   | 8       | 0.98     | 0.12    | 8       | 0.7%   | -0.04 [-0.14, 0.06] - |                                |
| Casal & Leon (1985)                       | 0.85     | 0.01   | 9       | 0.84     | 0.01    | 9       | 10.9%  | 0.01 [0.00, 0.02]     |                                |
| Cruz et al. (2015)                        | 0.93     | 0.02   | 8       | 0.95     | 0.02    | 8       | 7.6%   | -0.02 [-0.04, -0.00]  |                                |
| Demura et al. (2007)                      | 0.95     | 0.04   | 10      | 0.95     | 0.04    | 10      | 4.1%   | 0.00 [-0.04, 0.04]    | <b>_</b>                       |
| Giles & MacLaren (1984)                   | 0.85     | 0.04   | 6       | 0.92     | 0.03    | 6       | 3.5%   | -0.07 [-0.11, -0.03]  |                                |
| Graham et al. (2000)                      | 0.93     | 0.03   | 10      | 0.94     | 0.04    | 10      | 4.9%   | -0.01 [-0.04, 0.02]   |                                |
| Jenkins et al. (2008)                     | 0.99     | 0.01   | 13      | 0.99     | 0.001   | 13      | 11.8%  | 0.00 [-0.01, 0.01]    | +                              |
| McClaran & Wetter (2007)                  | 0.93     | 0.03   | 9       | 0.94     | 0.03    | 9       | 5.5%   | -0.01 [-0.04, 0.02]   |                                |
| Olcina et al.(2008)                       | 1.09     | 0.13   | 20      | 1.14     | 0.14    | 20      | 1.0%   | -0.05 [-0.13, 0.03]   |                                |
| Roy et al. (2001)                         | 0.94     | 0.04   | 12      | 0.93     | 0.03    | 12      | 5.4%   | 0.01 [-0.02, 0.04]    |                                |
| Stadheim et al. (2013)                    | 0.96     | 0.01   | 10      | 0.98     | 0.01    | 10      | 11.0%  | -0.02 [-0.03, -0.01]  |                                |
| Tarnopolsky et al. (1989)                 | 0.97     | 0.01   | 6       | 0.97     | 0.02    | 6       | 8.2%   | 0.00 [-0.02, 0.02]    |                                |
| Toner et al. (1982)                       | 0.94     | 0.05   | 8       | 0.94     | 0.05    | 8       | 2.5%   | 0.00 [-0.05, 0.05]    |                                |
| Van Soeren & Graham (1998)                | 0.83     | 0.01   | 6       | 0.84     | 0.01    | 6       | 10.2%  | -0.01 [-0.02, 0.00]   | -#-                            |
| Total (95% CI)                            |          |        | 181     |          |         | 181     | 100.0% | -0.01 [-0.01, 0.00]   | •                              |
| Heterogeneity: Tau <sup>2</sup> = 0.00; C | hi² = 54 | .75, c | lf = 17 | (P < 0.0 | 00001); | l² = 69 | 9%     |                       |                                |
| Test for overall effect: Z = 1.33         | 3 (P = 0 | ).18)  |         |          | ,,      |         |        |                       | -0.1 -0.05 0 0.05 0.1          |
|   |          | ,      |         |          |         |         |        |                       | Favors Placebo Favors Cattelne |

|  | Caffeine Placebo |   |          |         |           | )     |        | Mean Difference       | Mean Difference    |
|--|------------------|---|----------|---------|-----------|-------|--------|-----------------------|--------------------|
| Study or Subgroup                      | Mean             | SD  | Total    | Mean    | SD        | Total | Weight | IV, Random, 95% CI    | IV, Random, 95% CI |
| Acker-Hewitt et al. (2012)             | 77.4             | 15.9  | 10       | 74.4    | 11.8      | 10    | 2.0%   | 3.00 [-9.27, 15.27]   |                    |
| Anderson et al. (2000)                 | 53.8             | 6.1   | 8        | 51.7    | 6.1       | 8     | 8.4%   | 2.10 [-3.88, 8.08]    |                    |
| Bell et al. (1998)                     | 108.5            | 17.7  | 8        | 108.9   | 13.5      | 8     | 1.3%   | -0.40 [-15.83, 15.03] |                    |
| Bruce et al. (2000)                    | 99               | 17  | 8        | 94      | 19        | 8     | 1.0%   | 5.00 [-12.67, 22.67]  |                    |
| Casal & Leon (1985)                    | 81.8             | 3.4   | 9        | 80      | 3         | 9     | 34.0%  | 1.80 [-1.16, 4.76]    | _ <b>+</b> ∎       |
| Cruz et al. (2015)                     | 80               | 3.6   | 8        | 76.2    | 4.3       | 8     | 19.8%  | 3.80 [-0.09, 7.69]    |                    |
| Jenkins et al. (2008)                  | 104.7            | 5.5   | 13       | 97.9    | 4.8       | 13    | 19.0%  | 6.80 [2.83, 10.77]    | <b></b>            |
| McClaran & Wetter (2007)               | 59.5             | 6   | 9        | 56.6    | 3.4       | 9     | 14.7%  | 2.90 [-1.61, 7.41]    |                    |
| Total (95% CI)                         |                  |   | 73       |         |           | 73    | 100.0% | 3.36 [1.63, 5.08]     | •                  |
| Heterogeneity: Tau <sup>2</sup> = 0.00 | ; Chi² =         | 4.48,   | df = 7 ( | P = 0.7 | ′2); l² = | = 0%  |        |                       |                    |
| Test for overall effect: $Z = 3$       | 3.81 (P =        | -20 -10 0 10 20<br>Favors Placebo Favors Caffeine |          |         |           |       |        |                       |                    |

|  | Ca       | affeine | е        | PI      | acebo  | )        |        | Mean Difference     | Mean Difference                |  |  |
|--|----------|---------|----------|---------|--------|----------|--------|---------------------|--------------------------------|--|--|
| Study or Subgroup                          | Mean     | SD      | Total    | Mean    | SD     | Total    | Weight | IV, Random, 95% CI  | IV, Random, 95% CI             |  |  |
| Acker-Hewitt et al. (2012)                 | 2.17     | 0.4     | 10       | 1.75    | 0.5    | 10       | 6.5%   | 0.42 [0.02, 0.82]   |                                |  |  |
| Bell & McLellan (2002)                     | 5.7      | 1.8     | 8        | 4.6     | 1.7    | 8        | 1.5%   | 1.10 [-0.62, 2.82]  |                                |  |  |
| Bell & McLellan (2002)                     | 5.4      | 1.2     | 11       | 5.3     | 1.7    | 11       | 2.5%   | 0.10 [-1.13, 1.33]  |                                |  |  |
| Bell et al. (1998)                         | 9        | 0.7     | 8        | 7.75    | 0.5    | 8        | 5.3%   | 1.25 [0.65, 1.85]   |                                |  |  |
| Black et al. (2015)                        | 3.7      | 1       | 14       | 3       | 1      | 14       | 4.4%   | 0.70 [-0.04, 1.44]  |                                |  |  |
| Black et al. (2015)                        | 4.5      | 1.4     | 14       | 3.4     | 1      | 14       | 3.7%   | 1.10 [0.20, 2.00]   |                                |  |  |
| Cruz et al. (2015)                         | 7.55     | 0.52    | 8        | 6.01    | 0.47   | 8        | 5.9%   | 1.54 [1.05, 2.03]   | <b>-</b>                       |  |  |
| Demura et al. (2007)                       | 4.7      | 1.75    | 10       | 4.9     | 2.29   | 10       | 1.4%   | -0.20 [-1.99, 1.59] |                                |  |  |
| Giles & MacLaren (1984)                    | 3.62     | 0.62    | 6        | 2.78    | 0.83   | 6        | 4.0%   | 0.84 [0.01, 1.67]   |                                |  |  |
| Graham & Spriet (1995)                     | 4.26     | 0.69    | 8        | 3.66    | 0.64   | 8        | 4.9%   | 0.60 [-0.05, 1.25]  |                                |  |  |
| Graham et al. (1998)                       | 2.8      | 0.3     | 9        | 3.1     | 0.6    | 9        | 6.2%   | -0.30 [-0.74, 0.14] |                                |  |  |
| Graham et al. (1998)                       | 2.9      | 0.6     | 9        | 2.4     | 0.3    | 9        | 6.2%   | 0.50 [0.06, 0.94]   |                                |  |  |
| Graham et al. (2000)                       | 3.17     | 0.45    | 10       | 2.2     | 0.24   | 10       | 6.9%   | 0.97 [0.65, 1.29]   |                                |  |  |
| Greer et al. (2000)                        | 4.14     | 0.65    | 8        | 3.78    | 0.59   | 8        | 5.2%   | 0.36 [-0.25, 0.97]  | +•                             |  |  |
| Jenkins et al. (2008)                      | 9.7      | 0.7     | 13       | 8.2     | 0.7    | 13       | 5.6%   | 1.50 [0.96, 2.04]   | _ <b>_</b>                     |  |  |
| Olcina et al.(2008)                        | 4.12     | 1.82    | 20       | 3.92    | 1.95   | 20       | 2.7%   | 0.20 [-0.97, 1.37]  | <b>.</b>                       |  |  |
| Roy et al. (2001)                          | 3.75     | 2.15    | 12       | 2.9     | 1.6    | 12       | 1.9%   | 0.85 [-0.67, 2.37]  |                                |  |  |
| Stadheim et al. (2013)                     | 3.5      | 0.25    | 10       | 3.15    | 0.29   | 10       | 7.3%   | 0.35 [0.11, 0.59]   |                                |  |  |
| Stadheim et al. (2014)                     | 2.42     | 0.32    | 8        | 1.53    | 0.21   | 8        | 7.2%   | 0.89 [0.62, 1.16]   |                                |  |  |
| Tarnopolsky et al. (1989)                  | 2.58     | 0.35    | 6        | 2.48    | 0.26   | 6        | 6.8%   | 0.10 [-0.25, 0.45]  |                                |  |  |
| Van Soeren & Graham (1998)                 | 4.6      | 0.9     | 6        | 3.1     | 0.6    | 6        | 3.8%   | 1.50 [0.63, 2.37]   |                                |  |  |
| Total (95% CI)                             |          |         | 208      |         |        | 208      | 100.0% | 0.69 [0.46, 0.93]   | •                              |  |  |
| Heterogeneity: Tau <sup>2</sup> = 0.18; Cl | ni² = 77 | .14, di | f = 20 ( | P < 0.0 | 00001) | ; l² = 7 | 4%     |                     |                                |  |  |
| Test for overall effect: Z = 5.76          | 6 (P < 0 | .0000   | 1)       |         |        |          |        |                     | Favors Placebo Favors Caffeine |  |  |
|  |          |         |          | -       |        |          |        |                     |                                |  |  |
|  | Ca       | affein  | e        | PI      | acebo  | )        |        | Mean Difference     | Mean Difference                |  |  |
| Study or Subgroup                          | Mean     | SD      | Total    | Mean    | SD     | Total    | Weight | IV, Random, 95% CI  | IV, Random, 95% CI             |  |  |
| Acker-Hewitt et al. (2012)                 | 4.3      | 0.49    | 10       | 4.16    | 0.53   | 10       | 5.0%   | 0.14 [-0.31, 0.59]  |                                |  |  |
| Bell & McLellan (2002)                     | 3.1      | 0.5     | 11       | 3.2     | 0.7    | 11       | 4.2%   | -0.10 [-0.61, 0.41] |                                |  |  |
| Bell & McLellan (2002)                     | 4        | 0.5     | 8        | 3.3     | 0.3    | 8        | 5.6%   | 0.70 [0.30, 1.10]   |                                |  |  |

| Bell & McLellan (2002)                     | 4        | 0.5   | 8  | 3.3  | 0.3  | 8   | 5.6%   | 0.70 [0.30, 1.10]  |           | <b>_</b> |
|--|----------|-------|----|------|------|-----|--------|--------------------|-----------|----------|
| Bell et al. (1998)                         | 4.73 0   | ).11  | 8  | 4.23 | 0.09 | 8   | 11.3%  | 0.50 [0.40, 0.60]  |           | -        |
| Cruz et al. (2015)                         | 4.42 0   | ).28  | 8  | 3.92 | 0.28 | 8   | 7.8%   | 0.50 [0.23, 0.77]  |           | <b>_</b> |
| Giles & MacLaren (1984)                    | 4.68 0   | ).69  | 6  | 4.2  | 0.63 | 6   | 2.4%   | 0.48 [-0.27, 1.23] |           | •        |
| Graham & Spriet (1995)                     | 5.89 0   | ).41  | 8  | 4.74 | 0.25 | 8   | 6.7%   | 1.15 [0.82, 1.48]  |           |          |
| Graham et al. (1998)                       | 4.3      | 0.5   | 9  | 4    | 0.4  | 9   | 5.3%   | 0.30 [-0.12, 0.72] | -         |          |
| Graham et al. (1998)                       | 4.7      | 0.5   | 9  | 4.3  | 0.5  | 9   | 4.8%   | 0.40 [-0.06, 0.86] | -         | •        |
| Graham et al. (2000)                       | 5.57 0   | ).15  | 10 | 5.07 | 0.15 | 10  | 10.7%  | 0.50 [0.37, 0.63]  |           |          |
| Greer et al. (2000)                        | 3.85 0   | ).27  | 8  | 3.84 | 0.14 | 8   | 9.1%   | 0.01 [-0.20, 0.22] |           | <b></b>  |
| Roy et al. (2001)                          | 5.6 0    | ).65  | 12 | 5.45 | 0.65 | 12  | 4.1%   | 0.15 [-0.37, 0.67] |           |          |
| Stadheim et al. (2013)                     | 4.8      | 0.1   | 10 | 4.5  | 0.1  | 10  | 11.4%  | 0.30 [0.21, 0.39]  |           |          |
| Tarnopolsky et al. (1989)                  | 5.19 0   | ).36  | 6  | 4.5  | 0.21 | 6   | 6.7%   | 0.69 [0.36, 1.02]  |           | <b>_</b> |
| Van Soeren & Graham (1998)                 | 3.89 0   | ).22  | 6  | 3.5  | 0.52 | 6   | 4.9%   | 0.39 [-0.06, 0.84] | -         | <b></b>  |
| Total (95% CI)                             |          | 1     | 29 |      |      | 129 | 100.0% | 0.42 [0.29, 0.55]  |           | •        |
| Heterogeneity: Tau <sup>2</sup> = 0.04; Ch |          |       |    |      |      |     |        |                    |           |          |
| Test for overall effect: Z = 6.36          | (P < 0.0 | 0001) |    |      |      |     |        |                    | -1 -0.5 ( | U U.5 1  |

Favors Placebo Favors Caffeine